Accordingly, OEA-DS, through activation of PPAR-α, as well as through the effect on adiponectin expression, causes an increase in beta oxidation of fatty acids, slowing down lipid accumulation in the liver, and, thus, inhibiting the development of fatty liver dystrophy. The gene discussed is ADIPOQ; the disease is Dravet syndrome.